Related Experiment Videos
[The treatment of intestinal diseases with Mutaflor. A multicenter retrospective study]
Abstract:
The preparation Mutaflor contains a defined strain of physiological E. coli bacteria. One hundred and sixty-seven physicians documented the treatment of 1,074 patients suffering from functional or chronic inflammatory bowel disease. For all indications the tolerance of Mutaflor was judged to be good to very good in over 90% of the cases. Adverse reactions which needed treatment or led to termination of the therapy, were reported in 1.5% of the cases. Initially occurring side effects, which did not need treatment and disappeared spontaneously, were observed in 2.8% of the cases. Interactions with additional or concomitant drugs did not occur. As a parameter for the evaluation of efficacy, the subjective assessment of the results by physicians and patients was used. In 84% of the patients with functional intestinal disorders and 78% of the patients with chronic inflammatory bowel disease results of treatment were judged to be good to very good.
Insights
Mutaflor, a preparation of E. coli bacteria, demonstrated good to very good tolerance in over 90% of patients with bowel disorders. Treatment efficacy was rated highly by physicians and patients for both functional and inflammatory bowel diseases.
Area of Science:
- Microbiology
- Gastroenterology
Background:
- The gut microbiome plays a crucial role in digestive health.
- Dysbiosis is implicated in various gastrointestinal disorders.
- Probiotic interventions are explored for managing bowel conditions.
Purpose of the Study:
- To evaluate the safety and efficacy of Mutaflor in patients with functional and chronic inflammatory bowel disease.
- To assess patient and physician-reported outcomes of Mutaflor treatment.
Main Methods:
- A multicenter study involving 167 physicians documenting 1,074 patients.
- Patients diagnosed with functional or chronic inflammatory bowel disease.
- Data collection focused on treatment tolerance, adverse reactions, and efficacy assessments.
Main Results:
- Mutaflor exhibited good to very good tolerance in over 90% of cases.
- Adverse reactions requiring intervention occurred in only 1.5% of patients.
- Physician and patient assessments indicated good to very good treatment outcomes in 84% of functional intestinal disorder patients and 78% of chronic inflammatory bowel disease patients.
Conclusions:
- Mutaflor is well-tolerated and effective for managing functional and chronic inflammatory bowel diseases.
- The preparation shows a favorable safety profile with minimal adverse events.
- Subjective assessments by physicians and patients support Mutaflor's therapeutic value in gastrointestinal disorders.